Celldex Therapeutics (CLDX) Non-Current Debt (2010 - 2013)
Celldex Therapeutics (CLDX) posted quarterly Non-Current Debt of $10.1 million for Q1 2013, up 2.12% year-over-year from $9.9 million in Q1 2012, and up 75.77% quarter-over-quarter from $5.7 million in Q4 2012.
Celldex Therapeutics (CLDX) Non-Current Debt (2010 - 2013) Analysis & Trends
Celldex Therapeutics' Non-Current Debt history runs 4 years deep, the most recent figure standing at $10.1 million for Q1 2013.
- In Q1 2013, Non-Current Debt rose 2.12% year-over-year to $10.1 million; the TTM figure through Mar 2013 stood at $10.1 million (up 2.12% YoY), while the FY2012 annual figure was $5.7 million, down 36.21% from the prior year.
- Non-Current Debt for Q1 2013 stood at $10.1 million, up from $5.7 million in the prior quarter.
- The five-year high for Non-Current Debt was $15.0 million in Q1 2011, with the low at $5.7 million in Q4 2012.
- The 4-year median for Non-Current Debt is $10.0 million (2011), against an average of $10.1 million.
- Peak annual rise in Non-Current Debt reached 38.06% in 2012, while the deepest fall reached 36.21% in 2012.
- Celldex Therapeutics' Non-Current Debt stood at $8.9 million in 2010, then gained by 1.34% to $9.0 million in 2011, then slumped by 36.21% to $5.7 million in 2012, then surged by 75.77% to $10.1 million in 2013.
- Business Quant data shows CLDX's Non-Current Debt at $10.1 million in Q1 2013, $5.7 million in Q4 2012, and $7.3 million in Q3 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2013 | 10.10 Mn |
| Dec 31, 2012 | 5.75 Mn |
| Sep 30, 2012 | 7.33 Mn |
| Jun 30, 2012 | 13.90 Mn |
| Mar 31, 2012 | 9.89 Mn |
| Dec 31, 2011 | 9.01 Mn |
| Sep 30, 2011 | 11.02 Mn |
| Jun 30, 2011 | 10.07 Mn |
| Mar 31, 2011 | 15.00 Mn |
| Dec 31, 2010 | 8.89 Mn |